Skip to content

Total Equity at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$491.41M+3.3%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$2.28B-38.2%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
$543.45M-23.5%
AbbVie logo
AbbVieABBV
-$6.66B-569%
ALN
Alnylam PharmaceuticalsALNY
Royalty Pharma logo
Royalty PharmaRPRX

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's total equity?
Arrowhead Research (ARWR) reported total equity of $613.98M in Q1 2026.
How has Arrowhead Research's total equity changed year-over-year?
Arrowhead Research's total equity decreased by 10.1% year-over-year, from $683.32M to $613.98M.
What is the long-term trend for Arrowhead Research's total equity?
Over 5 years (2020 to 2025), Arrowhead Research's total equity has grown at a 0.2% compound annual growth rate (CAGR), from $461.78M to $466.05M.
What does total equity mean?
The total value of the company that belongs to the shareholders after all debts are paid.
How do you interpret total equity?
An increase generally signals a stronger balance sheet and higher net asset value, while a decrease may indicate losses or significant share buybacks.
How does total equity compare across companies?
Essential for assessing solvency in biotech firms that rely on equity financing rather than debt.